| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
 |
|
Site Navigation
| ALS News & Research For postings of news or research links and articles related to ALS |
| Reply |
|
|
Thread Tools | Display Modes |
|
|
| ALS News & Research For postings of news or research links and articles related to ALS |
| Reply |
|
|
Thread Tools | Display Modes |
05-02-2017, 09:24 PM
|
#1 | |||
|
||||
|
Grand Magnate
|
Biohaven Advances Regulatory Efforts for BHV-0223, a Sublingual Form of ALS Therapy Rilutek
ALS Therapy Rilutek's Sublingual Version BHV- 223 is Focus of Biohaven Regulatory Efforts |
|||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Biohaven Pharmaceutical files for IPO | ALS News & Research | |||
| Biohaven Announces Orphan Drug Designation Request Granted For BHV-0223 In The Treatm | ALS News & Research | |||
| advances-and-challenges-in-the-dosage-form-design-for-the-treatment-of-parkinson | Parkinson's Disease | |||
Biohaven Advances Regulatory Efforts for BHV-0223, a Sublingual Form of ALS Therapy R
Linear Mode
